Drugs / QR12000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06716970 | Dec 2024 → Apr 2026 overdue | essential hypertension | Wuhan Createrna Science and Technology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QR12000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06716970 ↗ |